Abivax
Biotechnology Research • 
Paris, Île-de-France, France • 51-100 Employees
Company overview
| Headquarters | 7-11, Boulevard Haussmann, Paris, Île-de-France 75009, FR |
| Phone number | +33153830963 |
| Website | |
| SIC | 873 |
| Keywords | Biotechnology, R&D, Innovation, Crohn'S Disease, Ulcerative Colitis, Inflammatory Bowel Desease |
| Founded | 2013 |
| Employees | 51-100 |
| Socials |
Key Contacts at Abivax
Camilla Soenderby
Member Board Of Directors & Appointments And Compensation Committee
Rosie Dawes
Director Of Regulatory Affairs
Maxime Thomas
Director Regulatory Affairs
Phuong Tran
Director, Medical Affairs
Sophie Gibelli
Senior Gcp/Gvp Global Quality Director
Laurence Desroys Du Roure
Associate Director, Clinical Operations
Sunil Sabbani
Director - Cmc Api And Finished Formulation Process Transfer
Trinidad Mesa
Finance & Accounting Director
Amy Adams
Director, Data Management
Bhushan Kanumuri
Senior Director Statistical Programming
Abivax Email Formats
Abivax uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@abivax.com), used 67.3% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@abivax.com | 67.3% |
{first name}.{last name} | john.doe@abivax.com | 32.7% |
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod is an investigational, orally administered, once-daily therapy, which we believe has the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers.
Abivax revenue & valuation
| Annual revenue | $113,240 |
| Revenue per employee | $2,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $362,368 |
| Total funding | $911,000,000 |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Abivax has 42 employees across 8 departments.
Departments
Number of employees
Funding Data
Explore Abivax's funding history, including investment rounds, total capital raised, and key backers.
Abivax Tech Stack
Discover the technologies and tools that power Abivax's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
RUM
Video players
Miscellaneous
JavaScript libraries
Maps
JavaScript libraries
CDN
Font scripts
Databases
JavaScript libraries
Netherlands
Frequently asked questions
4.8
40,000 users
